Related by context. All words. (Click for frequent words.) 66 Tarvacin TM 66 Tarvacin 64 PXD# 64 CYT# 63 ganetespib 63 PEG Interferon lambda 63 Phase Ib 62 preclinical studies 62 Cotara 62 PEG SN# 62 AP# [003] 61 OncoVEX GM CSF 61 perifosine 61 Alpharadin 61 CBLB# 61 Reolysin 61 HGS ETR1 61 picoplatin 61 dacetuzumab 61 obatoclax 61 IMGN# 60 HuMax EGFr 60 imetelstat 60 XL# [003] 60 alvespimycin 60 axitinib 60 preclinical 60 HspE7 59 Phase 1b 59 cilengitide 59 CR# vcMMAE 59 MGCD# [001] 59 Azixa 59 Archexin 59 OXi# 59 Phase Ib study 59 GRN#L 59 XmAb# 59 Chemophase 59 PSMA ADC 59 pertuzumab 59 Phase Ib clinical 59 oral antiviral 59 ixabepilone 59 TG# [001] 59 MDV# 59 mapatumumab 59 Nanobody 59 tanespimycin 59 neratinib 59 phase IIa clinical 59 Azedra 59 preclinically 59 Phase Ib II 59 RDEA# 58 oral prodrug 58 AEOL # 58 SCH # 58 AEG# 58 forodesine 58 HCD# [002] 58 voreloxin 58 APOPTONE 58 Proxinium TM 58 INCB# [001] 58 phase Ib 58 pharmacodynamic 58 RG# [001] 58 teriflunomide 58 CCX# 58 viral kinetic 58 IMC A# 58 PF # [001] 58 NEUGENE 58 phase IIb 58 CoFactor 58 CA4P 58 elesclomol 58 IMA# 58 ADVEXIN 58 tivozanib 58 Bavituximab 58 carfilzomib 58 CBLC# 58 ZYBRESTAT 58 huC# DM4 57 pharmacodynamic properties 57 enzastaurin 57 antiviral efficacy 57 monoclonal antibody 57 Traficet EN 57 dirucotide 57 Carfilzomib 57 HuMax CD# 57 OncoVEX 57 MGCD# [002] 57 celgosivir 57 farletuzumab 57 CEQ# 57 elacytarabine 57 Debio 57 Amplimexon 57 phase IIb clinical 57 Virulizin ® 57 GLP toxicology studies 57 Cloretazine R VNP#M 57 adecatumumab 57 nimotuzumab 57 Phase 2a 57 antitumor activity 57 tolerability profile 57 lintuzumab 57 CUDC 57 REOLYSIN ® 57 MAP# 57 pomalidomide 57 BCX# 57 HQK 57 dose cohorts 57 elotuzumab 57 CLORETAZINE TM VNP#M 57 antiviral activity 57 JAK inhibitor 57 NP2 Enkephalin 57 BNC# 57 Allovectin 7 ® 57 Phase 2a trial 57 DAVANAT 56 Phase 1b clinical 56 tolerability 56 bortezomib 56 Exherin TM 56 eniluracil 56 HGS# 56 HCV protease inhibitor 56 Restanza 56 nab paclitaxel 56 seliciclib 56 PMX # 56 rNAPc2 56 PRT# 56 immunogenicity 56 preclinical efficacy 56 tesetaxel 56 IRX 2 56 MBP# [001] 56 BAY #-# 56 vascular disrupting agent 56 Sym# 56 Protectan CBLB# 56 Anthim 56 MAXY G# 56 ascending dose 56 Panzem R NCD 56 vemurafenib 56 gemcitabine 56 LymphoStat B 56 velafermin 56 romidepsin 56 tesmilifene 56 sunitinib 56 lumiliximab 56 Tesetaxel 56 Perifosine 56 tolerability profiles 56 EOquin TM 56 ALN RSV# 56 ProLindac 56 fluoropyrimidine 56 AQ4N 56 Tarvacin Anti Viral 56 pharmacodynamic PD 56 otelixizumab 56 Neuradiab 56 GAP #B# 56 torezolid phosphate 56 Valortim 56 ANA# 55 MAGE A3 ASCI 55 anti leukemic 55 PI3K inhibitor 55 MEK inhibitors 55 Nanobody ® 55 glufosfamide 55 Exelixis XL# 55 anti phosphatidylserine 55 Omacetaxine 55 Cotara R 55 CIMZIA TM 55 Aplidin 55 favorable pharmacokinetic profile 55 DermaVir Patch 55 pharmacokinetic PK 55 Phase IIa trial 55 MGd 55 teduglutide 55 mertansine 55 ASA# 55 elagolix 55 bafetinib 55 Enzastaurin 55 T DM1 55 GVAX 55 ZK EPO 55 tolerated dose MTD 55 blinatumomab 55 sapacitabine 55 TNFerade 55 phosphatidylserine PS targeting 55 NEUMUNE 55 BIBW 55 AEZS 55 vandetanib 55 Cloretazine ® 55 Hsp# inhibitor 55 HuLuc# 55 dose cohort 55 ongoing Phase 1b 55 Phase IIa clinical 55 AVN# [001] 55 antitumor 55 MKC# PP 55 Asentar 55 TOCOSOL Paclitaxel 55 R#/MEM # 55 GALNS 55 Bezielle 55 GRN# 55 BrachySil 55 pharmacokinetic PK study 55 MEK inhibitor RDEA# 55 dose escalation study 55 ToGA 55 Protexia R 55 amrubicin 55 CD# monoclonal antibody 55 Tyrima 55 docetaxel 55 indibulin 55 Rexin G 55 CRLX# 55 anticancer therapies 55 Tarceva TM 55 LEP ETU 55 Zybrestat 55 isavuconazole 55 SAR# [004] 55 ATL/TV# 55 Dacogen injection 55 zalutumumab 55 Zerenex 55 systemically administered 55 antibody MAb 55 bendamustine 55 relapsed refractory multiple myeloma 55 Factor VIIa 55 cannabinor 55 INGN 54 histone deacetylase HDAC inhibitor 54 Zolinza 54 PS# [001] 54 YONDELIS 54 ALN VSP 54 BiTE antibody 54 iroxanadine 54 ProSavin 54 oral ridaforolimus 54 Onconase 54 dose escalation 54 Atiprimod 54 BRAF inhibitor 54 nanoviricides 54 vivo efficacy 54 OvaRex R 54 aflibercept VEGF Trap 54 dose escalation trial 54 chemotherapeutic drug 54 HER2 positive metastatic breast 54 therapeutic monoclonal antibody 54 eculizumab 54 ipilimumab 54 TACI Ig 54 anticancer 54 radiolabeled monoclonal antibody 54 Imprime PGG 54 Alocrest 54 talabostat 54 Tovaxin 54 velafermin belinostat 54 CD# antibodies 54 daclizumab 54 IDX# 54 Bicifadine 54 Vitaxin 54 Azedra TM 54 dose limiting toxicities 54 ENMD # 54 Valortim ® 54 Pralatrexate 54 GATTEX 54 PCK# 54 Allovectin 7 54 docetaxel chemotherapy 54 TLR8 agonist 54 ELND# 54 OMP #M# 54 phase Ib clinical 54 talactoferrin 54 PEGPH# 54 MLN# 54 anticancer agent 54 Allovectin 7 R 54 bevacizumab Avastin ® 54 CYC# 54 pharmacokinetic profiles 54 Actilon 54 MEK inhibitor 54 INCB# [002] 54 vorinostat 54 deforolimus 54 Serdaxin 54 TRV# [001] 54 irinotecan chemotherapy 54 Phase 2a clinical 54 HGS ETR2 54 Aflibercept 54 MAb 54 gemcitabine carboplatin 54 Vicinium TM 54 HuMax CD4 54 RNAi therapeutic 54 milatuzumab 54 TELCYTA 54 FOLOTYN 54 CORT # 54 delafloxacin 54 novel anticancer 54 safety tolerability pharmacokinetic 54 PROCHYMAL 54 pralatrexate 54 RP# [002] 54 gefitinib 54 PRTX 54 Valortim R 54 cethromycin 54 Phase IIb clinical trials 54 NGX# 54 CTCE 54 ISIS # 54 vascular disrupting agents 54 Prochymal 54 ENMD 54 taxane 54 IMC #B 54 multicenter Phase 54 Fx #A 54 IMP# 54 TG# [003] 53 MultiStem 53 PROSTVAC TM 53 administered subcutaneously 53 Ceplene/IL-2 53 tremelimumab 53 phase IIa 53 Phase 1b trial 53 SRT# [003] 53 PEGylated interferon 53 IAP inhibitors 53 Ceflatonin 53 ELACYT 53 DACH platinum 53 investigational humanized monoclonal antibody 53 galiximab 53 ANG# 53 pharmacokinetic profile 53 Viramidine 53 depsipeptide 53 liposomal formulation 53 huN# DM1 53 riociguat 53 Cloretazine 53 immunomodulator 53 Trastuzumab 53 atacicept 53 regorafenib 53 viral kinetics 53 cancer immunotherapies 53 phase 2a 53 rBChE 53 samalizumab 53 Xcytrin 53 vidofludimus 53 triphendiol 53 valopicitabine 53 Phase #/#a 53 tubulin inhibitor 53 FTY# 53 PEG PAL 53 Preclinical studies 53 docetaxel Taxotere R 53 efficacy 53 pharmacokinetics PK 53 abiraterone 53 ALN TTR 53 LY# [003] 53 proteasome inhibitor 53 Advexin 53 DAVANAT R 53 Curaxin 53 oncolytic 53 investigational hepatitis C 53 subcutaneous formulation 53 satraplatin 53 gemcitabine cisplatin 53 PTH analogue 53 Copegus ribavirin 53 brentuximab vedotin SGN 53 Golimumab 53 PDX pralatrexate 53 isoform selective 53 BrachySil TM 53 drug conjugate 53 Atu# 53 refractory multiple myeloma 53 pradefovir 53 GAMMAGARD 53 MYDICAR ® 53 ASONEP 53 Phase 2b study 53 HCV polymerase inhibitor 53 Phase 1a 53 Cotara ® 53 Phase 1a clinical 53 KRN# 53 belinostat 53 nonclinical studies 53 metaglidasen 53 carboplatin 53 GLYX 53 Angiolix 53 Phase 2b trial 53 Triolex 53 Marqibo 53 MyVax R 53 NP2 53 vascular disrupting 53 radezolid 53 CGEN # 53 Phase III clinical 53 tezampanel 53 telaprevir VX 53 vilazodone 53 crizotinib PF # 53 trastuzumab DM1 T DM1 53 synthetic retinoid 53 Insegia 53 Revimmune 53 IgG1 antibody 53 radiation sensitizer 53 therapeutic antibody 53 ThermoDox 53 oxidative stress inducer 53 RH1 53 NTx TM -# 53 cediranib 53 Romidepsin 53 Pazopanib 53 REOLYSIN R 53 dimebon 53 docetaxel Taxotere ® 53 aflibercept 53 anticancer agents 53 combinability 53 apremilast 53 tamibarotene 53 Phase #b/#a clinical 53 Phase 2b clinical 53 nitazoxanide 53 ZD# [001] 53 ZACTIMA 53 pharmacodynamics 53 docetaxel Taxotere 53 masitinib 53 Phase IIb clinical 53 cytotoxic agents 53 Cethromycin 53 oral FTY# 53 thymalfasin 53 carboplatin paclitaxel 53 paclitaxel Taxol 53 Symadex 52 Neugene 52 solithromycin 52 ISTODAX 52 IAP inhibitor 52 edoxaban 52 Phase #b/#a 52 fosbretabulin 52 rindopepimut 52 DepoVax 52 PEGylated interferon beta 1a 52 NVA# 52 retaspimycin 52 NXL# 52 Curaxin CBLC# 52 TKM ApoB 52 erlotinib 52 Homspera 52 drug GAP #B# 52 trastuzumab DM1 52 angiogenesis inhibitor 52 TroVax 52 zanolimumab 52 RGB # 52 mitomycin 52 sorafenib 52 DermaVir 52 sunitinib malate 52 HDAC inhibitor 52 palifosfamide 52 pramlintide metreleptin combination 52 ridaforolimus 52 relapsed multiple myeloma 52 ATL# [001] 52 Aurexis 52 Vilazodone 52 personalized immunotherapy 52 epothilone 52 randomized discontinuation trial 52 Amigal 52 S/GSK# 52 melphalan prednisone 52 Thiovir 52 ANAVEX #-# [003] 52 TriRima 52 Radilex 52 multi kinase inhibitor 52 Panzem 52 PREZISTA r 52 orally bioavailable 52 protein kinase inhibitor 52 registrational 52 candidates bavituximab 52 Trofex 52 anticoagulant reversing agent 52 TRO# 52 Hyphanox 52 Darinaparsin 52 MOZOBIL 52 HDAC Inhibitor 52 GFT# 52 tezampanel NGX# 52 anti EGFR antibody 52 erlotinib Tarceva ® 52 VEGF Trap 52 EGEN 52 torezolid 52 AZD# 52 motesanib 52 orally dosed 52 tipifarnib 52 ARRY 52 posaconazole 52 Afatinib 52 DPX Survivac 52 interferon lambda 52 preclinical models 52 heavily pretreated patients 52 lapatinib Tykerb 52 FluCide 52 Radezolid 52 Trofex TM 52 IIa trial 52 XL# XL# 52 Phase IIb trials 52 LUX Lung 52 laquinimod 52 oral gallium 52 sulodexide 52 Aptivus ® 52 sorafenib Nexavar 52 tecarfarin 52 humanized antibody 52 Solazed 52 KNS # 52 iclaprim 52 FOLFOX chemotherapy 52 Troxatyl 52 tolerability pharmacokinetics 52 BRAF inhibitors 52 BENLYSTA ® 52 receptor tyrosine kinase inhibitor 52 trastuzumab Herceptin 52 EOquin 52 VELCADE melphalan 52 AVE# 52 BRIM2 52 mipomersen 52 GVAX ® 52 AACR NCI EORTC 52 Phase IIa 52 taxanes 52 rhC1INH 52 metastatic malignant melanoma 52 NKTR 52 bevacizumab Avastin 52 immunomodulatory 52 molecularly targeted 52 Ixempra 52 Phase IIa trials 52 Phase Ia 52 EndoTAG TM -1 52 refractory CLL 52 PARP inhibitor 52 ofatumumab 52 MYDICAR 52 ACTEMRA 52 resminostat 52 TELINTRA 52 MetMAb 52 LymphoStat B TM 52 pharmacodynamic markers 52 pharmacokinetics 52 integrase inhibitor 52 CCR5 antagonist 52 Nanobodies 52 ponatinib 52 PDE4 inhibitor 52 entinostat 52 Vidofludimus 52 GSK# [001] 52 antitumor effects 52 Shigamabs ® 52 peg IFN 52 Cethrin R 52 EndoTAGTM 1 52 tgAAC# 52 evaluating tivozanib 52 JAK2 inhibitor 52 decitabine 52 lorvotuzumab mertansine 52 PSN# [002] 52 mTOR inhibitors 52 anti angiogenic 52 dasatinib 52 APD# 52 EFAPROXYN 52 TPI ASM8 52 Aclidinium 52 urate lowering 52 custirsen 52 cariprazine 52 Apoptone 52 Pegasys ® 52 oral Azacitidine 52 Nexavar ® 52 brostallicin 52 aclidinium 52 Amrubicin 52 Phase 1b clinical trials 52 oral Xeloda 52 Phase IIIb clinical 52 metastatic CRC 51 GRNVAC1 51 Hedgehog antagonist 51 PLX# 51 paclitaxel Taxol ® 51 relapsing multiple sclerosis 51 small molecule defensin 51 Phase III 51 Removab 51 Aurora kinase inhibitor 51 proteasome inhibitors 51 pharmacodynamic profile 51 Excellarate 51 Sphingomab 51 NeuroVax TM 51 tipranavir 51 ON #.Na 51 immunotherapeutic 51 glioblastoma multiforme GBM 51 chemotherapeutic agents 51 Daclizumab 51 Phase 2b 51 Ontak 51 CIMZIA ™ 51 Elotuzumab 51 CYT# potent vascular disrupting 51 nanopharmaceutical 51 ZFP Therapeutic 51 Panzem NCD 51 ALN TTR# 51 alemtuzumab MS 51 baminercept 51 Quinamed 51 Fodosine 51 olaparib 51 Teriflunomide 51 antibody 51 MVA BN R 51 oral anticancer 51 PHX# 51 H#N# VLP vaccine 51 adenovector 51 dalbavancin 51 Phase #b/#a trial 51 XL# SAR# 51 ocrelizumab 51 potent antitumor activity 51 AeroLEF TM 51 iSONEP 51 XL# XL# XL# XL# 51 limiting toxicity 51 MAXY alpha 51 VELCADE 51 #I TM# 51 XL# XL# XL# 51 BiTE 51 pharmacokinetic properties 51 Doxil ® 51 TLR9 agonist 51 EndoTAG 51 RAV# 51 dosing cohort 51 ozarelix 51 PLK1 SNALP 51 antisense 51 mitogen activated ERK kinase 51 stated Michelle Berrey 51 Oral NKTR 51 confirmatory Phase 3 51 multitargeted 51 Nasulin 51 antitumor effect 51 AEGR 51 gemcitabine Gemzar 51 AzaSite Plus 51 cancer immunotherapy 51 DexaSite 51 Aeroquin 51 Peg IFN 51 secondary efficacy endpoints 51 Nanobodies ® 51 tyrosine kinase inhibitor 51 Ampligen R 51 phase IIb study 51 vicriviroc 51 delta isoform 51 humanized monoclonal antibody 51 Annamycin 51 CXB# 51 AVONEX ® 51 hematological malignancies 51 GW# [003] 51 monoclonal antibodies 51 metastatic hormone refractory 51 afatinib 51 bevirimat 51 rituximab 51 Kahalalide F 51 NEUGENE antisense 51 ILLUMINATE 51 Aplidin R 51 chlorambucil 51 goserelin 51 immune modulatory 51 pharmacokinetic 51 PROSTVAC ® 51 eprotirome 51 paclitaxel cisplatin 51 OMNARIS HFA 51 lintuzumab SGN 51 Tamibarotene 51 Phenoptin 51 EGFR inhibitors 51 platinum refractory 51 proteasome inhibitor bortezomib 51 dosing regimens 51 Vaxfectin 51 Pharmacokinetics PK 51 VEGF receptor inhibitor 51 vismodegib 51 mycophenolate mofetil 51 dexpramipexole 51 oral deforolimus 51 antiangiogenic activity 51 mAb 51 peptide antigens 51 chemotherapy induced neutropenia 51 Stedivaze 51 Opexa 51 Exelixis compounds 51 Anticalin R 51 radionuclide therapy 51 DP b# 51 anticancer compound 51 Taxotere chemotherapy 51 Oncogenex 51 investigational compound 51 Alzhemed TM 51 T#I [002] 51 REOLYSIN 51 multicenter Phase II 51 investigational monoclonal antibody 51 CD3 monoclonal antibody 51 PRX# 51 DEB# 51 Telcyta 51 dose regimens 51 OHR/AVR# 51 rALLy trial 51 StemEx R 51 Pimavanserin 51 octreotide 51 anticancer activity 51 IND submission 51 Intravenous CP 51 kinase inhibitor 51 PegIFN 51 brentuximab vedotin 51 cangrelor 51 Epratuzumab 51 mg kg BID 51 novel peptide 51 Elesclomol 51 rFIXFc 51 alpha folate receptor 51 AVP #D# 51 darapladib 51 TroVax ® 51 Bendavia 51 Bortezomib 51 flavopiridol 51 maximally tolerated dose 51 bevacizumab 51 ISENTRESS 51 blinded randomized placebo controlled 51 MORAb 51 vosaroxin 51 GMX# 51 idarubicin 51 virus HCV protease inhibitor 51 Elacytarabine 51 JAK1 51 MT#/MEDI-# 51 IND enabling 51 ularitide 51 neuraminidase inhibitor 51 pharmacodynamics PD 51 AVEO 51 intravesical instillation 51 temsirolimus 51 recurrent NSCLC 51 omega interferon 50 seliciclib CYC# 50 Lenocta 50 ACTEMRA TM 50 Fludara 50 reslizumab 50 Listeria vaccine 50 null responder HCV 50 visilizumab 50 elvucitabine 50 novel VDA molecule 50 ImmunoVEX HSV2 50 Mipomersen 50 Lovaxin C 50 HER2 antibody 50 alkylating agent 50 pivotal Phase III 50 rALLy clinical trial 50 LibiGel Phase III 50 monoclonal antibody MAb 50 antiangiogenic therapy 50 EpCAM 50 safety tolerability 50 DXL# 50 pharmacokinetic equivalence 50 targeted radiotherapeutic 50 darinaparsin ZIO 50 AMN# [001] 50 cisplatin 50 Solid Tumors 50 Altastaph 50 Apaziquone 50 sitagliptin 50 Azedra ™ 50 #ME# 50 prospectively defined 50 cetuximab Erbitux ® 50 JAK3 50 chemoradiotherapy 50 Interferon beta 1a 50 orally administered inhibitor 50 TYKERB 50 ISF# 50 ANAVEX #-# [001] 50 capecitabine Xeloda R 50 Locteron 50 Phase 2b clinical trials 50 eltrombopag 50 investigational drug 50 anti CD3 antibody 50 dose escalation clinical 50 MVA BN 50 Delcath PHP System 50 Androxal TM 50 trastuzumab emtansine T DM1 50 phase IIb trial 50 ALKS 50 NPC 1C 50 refractory AML 50 RiVax ™ 50 CD# antibody [001] 50 Zalypsis 50 Panzem R 50 pharmacodynamic effects 50 anticancer therapy 50 arimoclomol 50 TOLAMBA 50 Kevetrin ™ 50 safety tolerability pharmacokinetics 50 Celator 50 glatiramer acetate 50 HGS ETR1 mapatumumab 50 histone deacetylase inhibitor 50 randomized controlled Phase 50 hGH CTP 50 randomized Phase III 50 NOX E# 50 immune modulator 50 intratumoral injection 50 EGFR antibodies 50 JAK inhibitors 50 OncoGel 50 RhuDex ® 50 analgesic efficacy 50 immunological responses 50 RLY# 50 OvaRex ® MAb 50 subcutaneous SC 50 Dapagliflozin 50 gefitinib Iressa 50 AVADO 50 panitumumab 50 Erlotinib 50 bardoxolone 50 JAK2 inhibitors 50 Dasatinib 50 immunotherapy 50 Hematide 50 Pemetrexed 50 non nucleoside 50 Phase II 50 subcutaneously administered 50 histone deacetylase HDAC 50 systemic RNAi therapeutic 50 anti angiogenic agents 50 FluINsure 50 forodesine HCl 50 mcg dose 50 Albuferon TM 50 Phase IIb III 50 paclitaxel poliglumex 50 relapsed SCLC 50 M Vax 50 BMS # 50 GlycoPEG GCSF 50 SUCCEED trial 50 LT NS# 50 CTAP# Capsules 50 Laquinimod 50 BiovaxID 50 VLP vaccine 50 Onalta ™ 50 low dose cytarabine 50 varespladib 50 non nucleoside HCV 50 bicifadine 50 Xanafide 50 standard chemotherapy regimen 50 Targretin 50 hematological cancers 50 LE DT 50 Sandostatin LAR Depot 50 SNT MC# 50 ADXS# 50 liver metastases 50 G#DT 50 CaPre TM 50 Interferon alpha 50 OncoVex 50 lapatinib 50 Fibrillex TM 50 CDDO Im 50 Phase III trials 50 LCP Tacro 50 Tanespimycin 50 ribavirin RBV